Table 2.
VEGF | P | ||
---|---|---|---|
| |||
1+ & +2 (Negative/Equivocal) (n=35) | +3 (Positive) (n=26) | ||
Age group (years) | |||
30-40 | 11 (31.4%) | 8 (30.8%) | 0.992 |
41-50 | 19 (54.3%) | 14 (53.8%) | |
>50 | 5 (14.3%) | 4 (15.4%) | |
Size of nodule (cm) | |||
<5 | 18 (51.4%) | 12 (46.2%) | 0.683 |
>5 | 17 (48.6%) | 14 (53.8%) | |
Nodularity | |||
STN | 14 (40.0%) | 16 (61.5%) | 0.096 |
Multi-nodular | 21 (60.0%) | 10 (38.5%) | |
TSH (Benign n=37) | |||
<1.39 | 11 (40.7%) | 2 (20.0%) | <0.001 |
1.4-2.49 | 14 (51.9%) | 1 (10.0%) | |
>2.5 | 2 (7.4%) | 7 (70.0%) | |
TSH (Malignant n=24) | |||
<1.39 | 4 (50.0%) | 1 (6.2%) | 0.004 |
1.4-2.49 | 4 (50.0%) | 5 (31.2%) | |
>2.5 | 0 (0.0%) | 10 (62.5%) | |
TSH (Total n=61) | |||
<1.39 | 15 (42.9%) | 3 (11.5%) | <0.001 |
1.4-2.49 | 18 (51.4%) | 6 (23.1%) | |
>2.5 | 2 (5.7%) | 17 (65.4%) |